Corpus Intelligence IC Memo — DESERT VIEW REGIONAL MEDICAL CENTER 2026-04-26 03:50 UTC
IC Memo — DESERT VIEW REGIONAL MEDICAL CENTER
Investment Committee Memorandum | NV | 25 beds | Grade C | EBITDA uplift $2.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

DESERT VIEW REGIONAL MEDICAL CENTER

CCN 291311 | nan, NV | 25 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

DESERT VIEW REGIONAL MEDICAL CENTER is a 25-bed suburban community hospital in nan, NV with $34.4M in net patient revenue and a 2.0% operating margin. The hospital serves a payer mix of 24.9% Medicare, 13.8% Medicaid, and 61.3% commercial.

Thesis: Turnaround. Our ML models identify $2.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.0% to 9.4% (+736bps).

Net Revenue HCRIS$34.4M
Current EBITDA COMPUTED$703K
Operating Margin COMPUTED2.0%
Occupancy HCRIS41.8%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS17.9%
Distress Probability ML50.5%

2. Market Context & Competitive Position

58
NV Hospitals
0.4%
State Median Margin
16
Comparable Hospitals

NV has 58 Medicare-certified hospitals with a median operating margin of 0.4%. The target's margin of 2.0% places it above the state median. Among 16 size-comparable peers (12-50 beds), the median margin is 0.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-50), prioritizing same-state peers. 16 hospitals in the comp set.

HospitalStateBedsRevenueMargin
DESERT VIEW REGIONAL MEDICAL C (Target)NV25$34.4M2.0%
CARSON VALLEY MEDICAL CENTERNV23$84.3M6.8%
BANNER CHURCHILL COMMUNITY HOSNV25$69.2M6.8%
DIGINTY HEALTH ST ROSE DOMINICNV32$61.5M12.2%
HUMBOLDT GENERAL HOSPITALNV25$58.8M-37.3%
PAM REHAB HOSP OF CENTENNIAL HNV44$35.7M29.1%
WILLIAM BEE RIRIE HOSPITALNV25$35.1M-17.9%
MESA VIEW REGIONAL HOSPITALNV25$34.9M-4.2%
BOULDER CITY HOSPITALNV25$30.7M-13.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$723K+210bp18mo
Cost to Collect4.5%2.5%$689K+200bp12mo
Denial Rate Reduction12.0%6.5%$682K+198bp12mo
A/R Days Reduction5200.0%3800.0%$419K+122bp9mo
Clean Claim Rate88.0%96.0%$22K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$723K
Cost to Collect
$689K
Denial Rate Reduction
$682K
A/R Days Reduction
$419K
Clean Claim Rate
$22K
Total EBITDA Uplift$2.5M
Current EBITDA$703K
+ RCM Uplift+$2.5M
Pro Forma EBITDA$3.2M
Current Margin2.0%
Pro Forma Margin9.4%
WC Released (1x)$1.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.1M$30.0M27.74x94.4%
Base (11x exit)10.0x11.0x$1.1M$33.3M30.84x98.5%
Bull Case9.0x11.0x$973K$42.0M43.22x112.4%
Bull (12x exit)9.0x12.0x$973K$46.2M47.45x116.4%
Bear Case11.0x10.0x$1.2M$17.0M14.26x70.2%
Bear (11x exit)11.0x11.0x$1.2M$19.0M16.01x74.1%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighElevated distress probabilityModel estimates 50.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 16 hospitals with 12-50 beds
  • Same-state prioritization (n=17)
  • Comp margins: P25=-18.4% / P50=0.1% / P75=8.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.